Development and Technical and Clinical Validation of a Quantitative Enzyme-Linked Immunosorbent Assay for the Detection of Human Antibodies to Hepatitis B Surface Antigen in Recipients of Recombinant Hepatitis B Virus Vaccine

Pierre Cambron,* Jeanne-Marie Jacquet, Bernard Hoet, and Marc Lievens

GlaxoSmithKline Biologicals, Rue de l’Institut 89, Rixensart, Belgium

Received 20 November 2008/Returned for modification 10 February 2009/Accepted 10 June 2009

Hepatitis B infection is a global health problem but most acutely affects developing countries (16). Currently, there is no effective therapy against hepatitis B, whose disease spectrum ranges from asymptomatic disease to chronic liver diseases, including cirrhosis and hepatocellular carcinoma. Prevention of the illness through vaccination remains the method of choice for its control and eradication. Active immunization against hepatitis B infection can be achieved using vaccines containing either inactivated hepatitis B virus (HBV) surface protein (HBsAg) physicochemically purified from plasma from HBV human carriers or recombinant surface antigen produced by transfer of the S gene of HBV coding for HBsAg to an appropriate plasmid that is then inserted into the desired expression vector. The recombinant vaccine manufactured by GlaxoSmithKline Biologicals (GSK) is produced in yeast and is antigenically similar to plasma-derived HBsAg (4). Clinical studies of this recombinant vaccine either formulated as a single-component vaccine (Engerix-B; trademark of GSK) or formulated in combination with other antigens such as hepatitis A vaccine (Twinrix; trademark of GSK) or pediatric diphtheria-tetanus-pertussis-based vaccines (such as Infanrix hexa and Tritanrix HepB; trademarks of GSK) have proven their efficacy and immunogenicity (5).

To date, commercial assays from Abbott Laboratories have been used at GSK to quantify the immune response to HBV vaccines in terms of antibodies against HBsAg (anti-HBs). However, since these assays are no longer commercially available in Europe, GSK has developed an in-house assay with adequate technical and clinical performance to ensure long-term supply of an assay with consistent quality. This paper describes the development, technical validation, and the clinical assessment of the new anti-HBs in-house assay.

MATERIALS AND METHODS

Selection of the immunological ELISA format. A sandwich enzyme-linked immunosorbent assay (ELISA) format was selected whereby specific anti-HBs antibodies were sandwiched between precoated HBsAg passively adsorbed onto the microplate and HBsAg tagged with horseradish peroxidase (HRP). Because the purpose of HBV vaccination is to protect against possible future contact with the wild-type virus, native HBsAg ad and ay subtypes (11), purified from plasma from HBV human carriers, were used as the solid phase. Quantification of antibodies raised by vaccination used HRP conjugate prepared from the recombinant HBsAg adw2 subtype, similar to that contained in the GSK vaccine (8), tagged with HRP.

Preparation of the HBsAg-precoated plates. Microplates were passively coated with 100 μl of a mixture (wt/wt) of native human HBsAg ad and ay subtypes (15) from The Binding Site (San Diego, CA) at 1 μg/ml in carbonate buffer (pH 9.5) for 24 h at room temperature. The plates were then washed four times with distilled water supplemented with NaCl (9 g/liter) and Tween 20 (Merck) and blocked with 200 μl of phosphate-buffered saline (PBS; 0.0095 M [pH 7.4]).
TABLE 1. Clinical studies retested with the anti-HBs in-house assay

| Study | Population         | Vaccine group          | Reference assay | No. of patients in group to be tested | Time point(s) | Rationale                                                                 |
|-------|--------------------|------------------------|-----------------|--------------------------------------|---------------|---------------------------------------------------------------------------|
| A     | 50–70 yr old       | Experimental HepB      | RIA             | 72 (subset)                          | PI, mo 1      | Verify concordance with AUSAB RIA in an elderly population which reaches lower seroprotection rate and GMT than in adults 18–40 yr old |
|       |                    | formulation            |                 |                                      |               | Engerix-B                                                                |
|       |                    |                        |                 |                                      | PI, mo 1      |                                                                           |
|       |                    |                        |                 |                                      | PII, mo 6     |                                                                           |
|       |                    |                        |                 |                                      | PIII, mo 7    |                                                                           |
| B     | Adult nonresponders | Experimental HepB      | RIA             | 58 (all)                             | Pre           | Verify concordance with AUSAB RIA in a difficult population and check specificity of anti-HBs in-house assay on prevaccination samples |
|       |                    | formulation            |                 |                                      |               | Engerix-B                                                                |
|       |                    |                        |                 |                                      | PI, mo 1      |                                                                           |
|       |                    |                        |                 |                                      | PII, mo 2     |                                                                           |
|       |                    |                        |                 |                                      | PII, mo 6     |                                                                           |
|       |                    |                        |                 |                                      | PIII, mo 7    |                                                                           |
| C     | 11–18 yr old       | Engerix-B              | RIA             | 72 (subset)                          | PI, mo 1      | Verify concordance with AUSAB RIA after vaccination with a vaccine from another manufacturer |
|       |                    |                        |                 |                                      |               | Recombivax<sup>c</sup>                                                    |
|       |                    |                        |                 |                                      | PII, mo 2     |                                                                           |
|       |                    |                        |                 |                                      | PII, mo 6     |                                                                           |
|       |                    |                        |                 |                                      | PIII, mo 7    |                                                                           |
| D     | 18–40 yr old       | Engerix old 1          | EIA             | 72 (subset)                          | PII, mo 6     | Verify concordance with AUSAB EIA following different formulations of the same vaccine |
|       |                    |                        |                 |                                      |               | Engerix old 2                                                             |
|       |                    |                        |                 |                                      | PIII, mo 7    |                                                                           |
|       |                    |                        |                 |                                      |               | Engerix                                                                  |
| E     | 12–15 yr old       | Ambirix 720/20         | RIA, EIA        | 140 (all)                            | PIII, mo 7    | Verify concordance with AUSAB RIA and AUSAB EIA                           |
|       |                    |                        |                 |                                      |               | Twinrix 360/10                                                            |
| F     | Children <1 yr old | Infanrix hexa          | RIA             | 50 (subset)                          | Pre           | Verify concordance with AUSAB RIA after vaccination with HBV in combined pediatric vaccines |
|       |                    |                        |                 |                                      |               | Infanrix penta + Hiberix                                                  |
|       |                    |                        |                 |                                      | PII, mo 6     |                                                                           |
|       |                    |                        |                 |                                      | PII, mo 8     |                                                                           |
|       |                    |                        |                 |                                      | PIII, mo 9    |                                                                           |
| G     | Children <1 yr old | Infanrix hexa          | EIA             | 62 (all)                             | Pre, mo 1.5   | Verify concordance with AUSAB EIA after vaccination with HBV in combined pediatric vaccines |
|       |                    |                        |                 |                                      |               | Infanrix penta + Hiberix                                                  |
|       |                    |                        |                 |                                      | PIII, mo 7    |                                                                           |
|       |                    |                        |                 |                                      | PIII, mo 15   |                                                                           |
|       |                    |                        |                 |                                      | PIV, mo 6     |                                                                           |

<sup>a</sup> Engerix old 1, previous formulation, containing thiomersal as a preservative; Engerix old 2, previous formulation, using thiomersal during the production process.
<sup>b</sup> Pre, sample taken prior to vaccination; PI to PIV, postdose months 1 to 4; mo 1, mo 2, etc., study month 1, study month 2, etc.
<sup>c</sup> Nonresponders are healthy adults with an anti-HBs antibody concentration of <10 mIU/ml 2 to 5 months after having received at least four doses of HBV.
<sup>d</sup> Recombivax is a trademark of Merck & Co.
supplemented with enzymatically hydrolyzed 0.1% casein (Sigma) and 0.5 ml/liter Proclin-300 (Supelco) as a preservative for 24 h at room temperature. Plates were washed four times with distilled water with 0.05% Tween 20 and 10g/liter saccharose (Sigma) and then dried overnight in a laminar flux. Each microplate was individually packed in a sealed aluminum bag that included desiccant.

Preparation of HBsAg-HRP conjugate. The recombinant HBsAg adw2 subtype was conjugated to sodium periodate-oxidized HRP (type VI RZ 3.0; Sigma) by a modification of the original method of Nakane et al. (7). Half a milliliter of a freshly prepared aqueous solution of 0.14 M sodium periodate solution (Aldrich) was added to 1 ml of 50 mg/ml HRP solution in distilled water and gently stirred for 30 min in the dark in order to generate active aldehyde functions on the hydroxyl groups of the several carbohydrate moieties. Then the HRP-aldehyde solution was chromatographically separated from periodate by gel filtration (Sephadex G-25) and quantified by absorbance at 403 nm. (A 1-mg/ml amount of oxidized HRP displays an optical density at 403 nm [OD403] of 1.6). The molar ratio between oxidized HRP after separation and the HBsAg to be coupled was 2.0.

The HBsAg solution previously dialyzed overnight at 4 to 8°C against 0.1

| Antibody concn (mIU/ml) | 0.95th percentile |
|-------------------------|-------------------|
| 2.92                    | 14.41             |
| 5.84                    | 8.59              |
| 11.69                   | 6.31              |
| 23.38                   | 4.51              |
| 46.75                   | 4.11              |
| 93.50                   | 3.12              |
| 187.00                  | 1.60              |

* The calibration curve is based on the distribution of the percentage of the absolute values of the relative bias (RE) for the complete set of standard points (0.95 percentile), where % RE = [(recalculated value – assigned value)/assigned value] × 100%.

95% CIs

| Coefficient | SE   | t-statistic | significance | Lower limit | Upper limit |
|-------------|------|-------------|--------------|-------------|-------------|
| Constant    | -0.0051 | 0.0097   | -0.5183     | 0.6055      | -0.0244     | 0.0143      |
| Log Human plasma | 1.0055 | 0.0054 | 186.6627 | 0.0000 | 0.9948 | 1.0162 |

SE = standard error

Linear regression: FBS / Hum-plasma

FIG. 1. Linear regression between FBS and human-plasma anti-HBs free as diluent. Hum-plasma, human plasma.
mol/liter sodium carbonate buffer (pH 9.5) was mixed with the HRP-aldehyde solution for 2 h at room temperature in the dark in order to generate Schiff's bases between the primary amine groups on HBsAg and the aldehyde groups present on the oxidized HRP. Remaining reactive aldehyde groups were blocked by adding 2 M Tris solution at a rate of 22 μl per mg of HRP-aldehyde and incubation for 30 min at room temperature. Subsequently the Schiff bases were reduced for 30 min at 4°C by the addition of 0.2 M sodium borohydrure (Aldrich) at a rate of 10 μl/mg of HRP-aldehyde engaged in the conjugation process. The HBsAg-HRP was chromatographically separated by gel filtration on Ultrogel AcA-34 (Amersham Biosciences) equilibrated with 0.05 M Tris buffer (pH 7.5) containing 0.5 ml/liter Tween 20. Finally, the fractions containing the HBsAg-HRP conjugate were pooled, supplemented with 10 g/liter bovine serum albumin (BSA) (Cohn fraction V; Serologicals) and 2 ml/liter Proclin-300 and stored at 4 to 8°C after filtration on a 0.2-μm-pore filtering device.

FIG. 2. Observed values and the model predictions for linearity assessment. For groups 1 and 4, the prediction line for each sample is superimposed with the prediction line for the mean sample within each group.

### TABLE 3. Accuracy of anti-HBs in-house assay in terms of human anti-HBV immunoglobulin

| Theoretical antibody concn (mIU/ml) | Measured antibody concn (mIU/ml) | % Recovery |
|------------------------------------|----------------------------------|------------|
| 3.3                                | 3.4                              | 100.4      |
| 6.3                                | 5.6                              | 90.4       |
| 6.3                                | 5.8                              | 93.4       |
| 10.4                               | 9.8                              | 94.2       |
| 10.4                               | 9.4                              | 90.3       |
| 20.8                               | 19.9                             | 95.5       |
| 20.8                               | 18.9                             | 90.8       |
| 41.5                               | 42.0                             | 101.2      |
| 41.5                               | 41.7                             | 100.4      |
| 82.6                               | 81.1                             | 98.2       |
| 82.6                               | 80.1                             | 96.9       |
| 163.9                              | 129.9                            | 79.3       |
| 163.9                              | 150.0                            | 91.5       |
| 476.2                              | 446.0                            | 93.7       |
| 909.1                              | 840.6                            | 92.5       |
| 2,000.0                            | 1,967.9                          | 98.4       |
| 3,333.3                            | 3,304.4                          | 99.1       |
| 5,000.0                            | 5,048.4                          | 101.0      |
| 10,000.0                           | 9,885.2                          | 98.9       |

The geometric mean recovery was 94.9%. The 95% CI lower and upper limits were 92.2% and 97.6%, respectively.

### TABLE 4. Demonstration of assay linearity

| Group | Slope       | 95% CI Lower limit | 95% CI Upper limit |
|-------|-------------|--------------------|--------------------|
| 1     | −0.9990     | −1.0318            | −0.9662            |
| 2     | −0.9910     | −1.0348            | −0.9472            |
| 3     | −0.9802     | −1.0180            | −0.9423            |
| 4     | −0.9976     | −1.0722            | −0.9230            |

Ten samples with concentrations between 100 and 51,895 mIU/ml were grouped into four groups according to the predilution applied to reach the upper limit of the analytical range. Shown are the estimated slope for each predilution group with its 95% CI using a mixed model with log dilution, group, and samples as factors.

mol/liter sodium carbonate buffer (pH 9.5) was mixed with the HRP-aldehyde solution for 2 h at room temperature in the dark in order to generate Schiff's bases between the primary amine groups on HBsAg and the aldehyde groups present on the oxidized HRP. Remaining reactive aldehyde groups were blocked by adding 2 M Tris solution at a rate of 22 μl per mg of HRP-aldehyde and incubation for 30 min at room temperature. Subsequently the Schiff bases were reduced for 30 min at 4°C by the addition of 0.21 M sodium borohydrure (Aldrich) at a rate of 10 μl/mg of HRP-aldehyde engaged in the conjugation process. The HBsAg-HRP was chromatographically separated by gel filtration on Ultrogel AcA-34 (Amersham Biosciences) equilibrated with 0.05 M Tris buffer (pH 7.5) containing 0.5 ml/liter Tween 20. Finally, the fractions containing the HBsAg-HRP conjugate were pooled, supplemented with 10 g/liter bovine serum albumin (BSA) (Cohn fraction V; Serologicals) and 2 ml/liter Proclin-300 and stored at 4 to 8°C after filtration on a 0.2-μm-pore filtering device.
Preparation and calibration of anti-HBs antibody standard. A pool of sera from HBV vaccine recipients with high levels of anti-HBs was diluted in fetal bovine serum (FBS; HyClone) containing 0.2 g/liter thymol (Sigma) and 100 µg/ml gentamicin sulfate (Sigma) as preservatives. After adjustment to around 190 mIU/ml, referring to the 1st International Reference Preparation (1st IRP) for anti-hepatitis B immunoglobulin (1), the standard preparation was dispensed from the standard curve generated by the WHO preparation using a four-parameter logistic fitting algorithm.

Preparation of assay controls. Four anti-HBs controls were prepared from separated pools of recalculated human plasma. The negative control (CN-1) was nonreactive for anti-HBs antibody. CB1-1 was spiked with serum obtained from a recipient of HBV vaccine and had an antibody level of 6.7 mIU/ml. CM-1 had a level of 18.1 mIU/ml and was spiked with serum of hospital origin. CM1-100 was unspiked and had a level of 6,436 mIU/ml. CH-100 was liquid and stored at 20°C. At the time of use, CN1-1, CB1-1, and CM1-100 were reconstituted with 1 ml of distilled water and then serially diluted (neat plus six steps) with FBS and incubated on four different lots of precoated plates. At the same time, serial dilutions in human recalculated plasma free of anti-HBs antibody ranging between 1.58 mIU/ml and 200.00 mIU/ml of one reference ampoule (1st IRP, lot 1977-W1042), freshly reconstituted according to IRP instructions, were incubated. Consequently, 96 measures based on serial dilutions were obtained. After correction for their respective dilution factor, the average concentration of the 96 individual values was determined. The values obtained before correction for dilution were extrapolated from the standard curve generated by the WHO preparation using a four-parameter logistic fitting algorithm.

Collection, preparation, and storage of test samples. Whole blood from healthy recipients of HBV vaccine was collected after informed consent was obtained. The Pokeweed mitogen stimulated lymphocytes were frozen and shipped to the WHO reference laboratory in a dry ice box. The lymphocytes were isolated from the buffy coat, separated pools of recalcified human plasma. The negative control (CN-1) was nonreactive for anti-HBs antibody. CB1-1 was spiked with serum obtained from a recipient of HBV vaccine and had an antibody level of 6.7 mIU/ml. CM-1 had a level of 18.1 mIU/ml and was spiked with serum of hospital origin. CM1-100 was unspiked and had a level of 6,436 mIU/ml. CH-100 was liquid and stored at 20°C. At the time of use, CN1-1, CB1-1, and CM1-1 were reconstituted with 0.5 ml of distilled water. Control CH1-100 was thawed and prediluted 1 to 100 with SSD before use.

Preincubation was performed with either an excess of a mix of native ad and ay HBsAg subtypes or adw2 HBsAg subtype for 2 h at 37°C. Specificity represents the difference in concentrations observed before and after inhibition expressed as a percentage of the corresponding concentration measured without inhibition.
evaluate the overall quality of the fitting of the standard curve, 167 standard
and RE.

incubated overnight at room temperature and then washed four times with 350
factors of 10 until the response was quantifiable.

higher than the highest anti-HBs antibody standard were diluted by successive
were stored at
obtained. Blood collection was approved by the relevant ethics committees. Sera

VOL. 16, 2009 QUANTITATIVE ELISA FOR DETECTION OF ANTI-HBsAg 1241

plate along with one set of anti-HBs standards. The average response and its

accuracy of the standard curves,

accuracy (3, 9, 10). An unweighted four-parameter logistic function was used to

shape. The four-parameter logistic function fits these data with a high degree of

was added to all wells. After 30 min of incubation in the dark, the color reaction

water. Plates were read in an ELISA reader at 450 nm against a reference filter

expressed in terms of the response

The backfit dose is the recalculated concentration of each standard obtained

CV (%)

1 1 >3,000 <187 10,000 1.652 777,731 754,411 3

100,000 0.200 736,191

2 1 >3,000 <187 10,000 1.438 644,921 649,409 1

100,000 0.180 654,897

3 1 >3,000 <187 10,000 1.705 833,075 823,976 2

100,000 0.215 814,878

a Average concentration determined at dilutions of 10,000 and 100,000.

The literature and current guidelines recommend an absolute value of RE of

Comparison of FBS and human-plasma as standard and sample diluent.
Ninety-eight samples covering a large range of anti-HBs concentrations were

assayed either with FBS or with human plasma as SSD, and the results were

compared by linear regression analysis after logarithmic transformation of the

data. In addition, a paired t test was performed on the geometric mean concentra-
tions (GMCs) obtained with each diluent.

Accuracy of recovery. In order to assess accuracy, one ampoule of the 1st IRP

for anti-HBs immunoglobulin (lot 1977-W1042) was reconstituted according to

the 1st IRP instructions and diluted to 10,000 mIU/ml in human plasma. Fur-

thermore, a 25-µl aliquot was added to different volumes of human plasma free

of anti-HBs antibodies in order to cover a concentration range from 3.3 to

100,000 mIU/ml. Then each sample was measured in the assay. The accuracy

was expressed as the geometric mean recovery percentage calculated for the whole set.

Assessment of repeatability and reproducibility of the anti-HBs in-house

assay under routine conditions. Precision was evaluated by a repeatability and

reproducibility experiment made on 12 sera covering a broad range of anti-HBs

antibody concentrations observed in routine conditions. To measure repeatabil-

ity (precision under minimum variable conditions), the same dilution of serum

was tested twice by the same certified operator on the same day, in the same run,

and with the same lot of reagents. To estimate the reproduc-

ibility (precision obtained under maximal variable conditions), all sera were

tested twice on the same plate on 4 different days (within a period of 2 weeks) by

two certified operators. A random three-way analysis of variance (ANOVA) with
day, operator, and sample as random factor was carried out (using proc mixed

from statistical SAS software) on log_{10} transformed concentrations. Computa-
tions were done on transformed values, but CVs were expressed from nontrans-

formed concentrations. In conclusion, 192 observations were generated (2 op-

erators × 4 days × 2 repeats × 12 samples).

Linearity and parallelism. Ten samples displaying concentrations between 100

and 51,895 mIU/ml were prediluted depending on their initial concentration to

reach the upper limit of the analytical range. Then six serial twofold dilutions

were applied to each sample. Each measured concentration was corrected for its

dilution. For the analysis, samples were gathered into four groups depending on

the first predilution applied: neat for group 1, 1 to 10 for group 2, 1 to 100 for
group 3, and finally 1 to 1,000 for group 4. A statistical analysis was performed

on the logarithmically transformed data in order to answer the following ques-
tions. Is the model globally linear, and are the slopes equal (parallel lines) from

group 1 to another? Are the slopes equal from one sample to the other within

average concentration (mIU/ml) Agreement (95% CI) Sensitivity (95% CI) Specificity (95% CI) Kappa McNemar

2 97.71 (96.53–98.58) 99.02 (98.08–99.58) 87.13 (79.00–92.96) 0.881 (0.830–0.931) 0.3833

2.6 97.82 (96.66–98.67) 98.53 (97.45–99.24) 92.08 (84.99–96.52) 0.891 (0.843–0.938) 0.5034

3.3 97.61 (96.40–98.49) 98.04 (96.84–98.88) 94.06 (87.52–97.79) 0.883 (0.835–0.931) 0.0525

3.9 96.74 (95.37–97.79) 96.94 (95.52–98.01) 95.05 (88.82–98.37) 0.847 (0.793–0.900) 0.0003

a n = 919.

b Test of dissymmetry in concordance.
each group? And finally, are the measured concentrations proportional to the applied successive dilutions?

**Specificity.** In order to establish specificity of the assay, 3 samples displaying a concentration below the cutoff and 10 samples displaying a very large range of concentrations were preincubated (vol/vol) with an excess of either a mixture of native ad and ay HBsAg subtypes (the combination used for the solid phase) or the adw2 HBsAg subtype (the one used for the preparation of the HRP conjugate) for 2 h at 37°C. The excess of antigen corresponded to 40 times the concentration of antigen used for the coated-plate preparation. The reference condition was similar to the experimental one but with PBS-BSA buffer instead of HBAg moieties. Then samples were tested with the anti-HBs in-house assay but also with the AUSAB EIA as a specificity control. Specificity was expressed as the difference in concentration observed before and after inhibition expressed as a percentage of the corresponding concentration measured without inhibition.

**Assessment of high-dose hook effect.** In order to rule out underestimation of the antibody concentration in samples with high levels of the analyte, three sera highly concentrated for anti-HBs were tested undiluted and at five consecutive 10-fold serial dilutions. There is no hook effect if the neat sample reports a concentration higher than the upper limit of the analytical range.

**Clinical cutoff and correlation with AUSAB RIA.** The assay cutoff has to be equal to or higher than the LOQ. In order to determine the most appropriate cutoff for seropositivity, different cutoffs from 2 to 3.9 mIU/ml were compared during the technical bridge of the new assay compared to AUSAB RIA. In this respect, the concentrations obtained with the new assay for 919 samples including prevaccination (7%) and postvaccination samples were compared to the historical results observed with the reference method. The cutoff was elected at a level for which the best balance was observed in terms of overall agreement, sensitivity, and specificity. In addition Deming’s regression was performed between double-positive samples in order to evaluate the correlation between both assays.

**Clinical validation of the assay.** The accepted serological correlate of protection of ≥10 mIU/ml against HBV infection was determined from studies that employed the AUSAB RIA. Therefore, the clinical validation included several studies having used AUSAB RIA. Three additional studies having used AUSAB EIA were also considered. In total, 4,180 samples from seven clinical studies were retested. These studies had been conducted in infants, adolescents, adults, and the elderly (>50 years of age). Subjects had received vaccination with various HBV vaccine-containing products, including vaccine combinations such as combined hepatitis A-HBV vaccine and combined diphtheria-tetanus-acellular pertussis-HBV-inactivated poliovirus vaccine (Table 1).
RESULTS

Preparation of the anti-HBs standard and its calibration to anti-HBs IRP lot 1702-1977. The distribution of the 96 individual concentrations obtained from the serial dilutions was Gaussian, and the CV of the recalculated concentrations was 4%. The final concentration of the freeze-dried in-house standard is expressed in mIU/ml. The calibration curve of the assay consists of one zero standard and seven positive standards ranging from 2.9 to 187.0 mIU/ml, namely 187.0, 93.5, 48.8, 23.4, 11.7, 5.8, and 2.9 mIU/ml. The loss of immunoreactivity after freeze-drying was 1.5% on average for two successive anti-HBs standard batches and therefore was considered negligible.

The calibration curve and its fitting algorithm. For all of the 167 standard curves, \( r^2 \) was >0.998. The 0.95th percentiles of the absolute values of RE were determined (Table 2). Accordingly we conclude that the accuracy of the standard curve within the analytical range set from 3.3 mIU/ml to 187 mIU/ml meets current guidelines (2, 13).

Analytical sensitivity. The individual ODs of the 64 replicates of the zero standard were normally distributed. The average response and the SD of all replicates were calculated. Then the upper limit of a one-sided 95% CI of the mean OD was injected into the standard curve generated at the same time and the corresponding concentration was extrapolated from the curve. Accordingly, the analytical sensitivity was estimated at 0.43 mIU/ml.

LOD. The OD corresponding to the upper limit of the one-sided 95% CI of the average OD response of the 142 negative samples was interpolated from the standard curve allowing the determination of an equivalent concentration expressed in mIU/ml. Accordingly, the LOD was set at 1.0 mIU/ml.

LOQ. The average lowest measured concentration was 0.68 mIU/ml with an SD of 0.26. The LOQ of the in-house test was set at 2.0 mIU/ml, equivalent to the one-sided upper limit of the 95% CI.

Comparison of FBS and human plasma as standard and sample diluent. The standard curves generated with either FBS or human plasma were superimposable (data not shown). The concentrations of the 98 samples measured with either FBS or human plasma were statistically compared by linear regression analysis. The interval for the slope was 1.0055 (95% CI, 0.9948 to 1.0162), and the intercept was 0.0051 (95% CI, −0.0244 to 0.0143) comprising 1 and 0, respectively, which indicated no significant difference between the two diluents (Fig. 1). Moreover, a paired \( t \) test showed no significant difference between means. (The observed difference in log was 0.0036, for which the 95% CI included 0 [−0.0060 to 0.0132].) Consequently FBS can be used instead of human plasma free.

| Study | No. of subjects/group | Time point | % Seroprotection in: | Vaccine group 1 | Vaccine group 2 | Vaccine group 3 |
|-------|-----------------------|------------|----------------------|----------------|----------------|----------------|
|       |                       |            | In-house assay       | RIA | EIA | In-house assay | RIA | EIA | In-house assay | EIA |
| A     | 72                    | PI, mo 1   | 15.3                 | 20.8 |      | 0.0            | 2.7 |      |                |     |
|       | 72                    | PI, mo 2   | 80.6                 | 81.9 |      | 23.6           | 26.4 |      |                |     |
|       | 72                    | PI, mo 6   | 95.8                 | 93.1 |      | 59.7           | 56.9 |      |                |     |
|       | 72                    | PI, mo 7   | 98.6                 | 98.6 |      | 81.9           | 83.3 |      |                |     |
| B     | 51                    | PI, mo 1   | 47.1                 | 49.0 |      | 63.6           | 63.6 |      |                |     |
|       | 51                    | PI, mo 2   | 60.8                 | 60.8 |      | 81.8           | 81.8 |      |                |     |
|       | 50                    | PI, mo 6   | 48.0                 | 42.0 |      | 85.2           | 81.5 |      |                |     |
|       | 47                    | PI, mo 7   | 72.3                 | 72.3 |      | 96.2           | 96.2 |      |                |     |
| C     | 100                   | PI, mo 1   | 2.0                  | 2.0  |      | 9.7            | 12.5 |      |                |     |
|       | 72                    | PI, mo 2   | 80.6                 | 68.1 |      | 68.1           | 69.4 |      |                |     |
|       | 72                    | PI, mo 6   | 93.1                 | 93.1 |      | 95.8           | 95.8 |      |                |     |
|       | 72                    | PI, mo 7   | 98.6                 | 97.2 |      | 100.0          | 100.0|      |                |     |
| D     | 72                    | PI, mo 7   | 97.2                 | 95.8 |      | 97.2           | 97.2 | 97.2 | 97.2           |     |
| E     | 134                   | PI/II, mo 2| 53.0                 | 40.3 | 41.8 | 90.4           | 86.8 | 86.8 |                |     |
|       | 145                   | PI/III, mo 7 | 99.3               | 98.6 | 99.3 | 100.0          | 100.0| 100.0|                |     |
| F     | 50                    | Pre        | 13.8                 | 16.9 |      | 12.2           | 12.2 |      |                |     |
|       | 50                    | PI, mo 6   | 98.0                 | 98.0 |      | 96.0           | 96.0 |      |                |     |
|       | 50                    | PI, mo 8   | 94.0                 | 94.0 |      | 100.0          | 100.0|      |                |     |
|       | 50                    | PI, mo 9   | 100.0                | 100.0|      | 100.0          | 100.0|      |                |     |
| G     | 34                    | Pre, mo 1.5| 52.9                 | 49.0 | 59.6 | 68.4           |      |      |                |     |
|       | 47                    | PI, mo 7   | 100.0                | 100.0|      | 95.9           | 95.0 |      |                |     |
|       | 53                    | PI, mo 15  | 96.6                 | 96.6 | 93.0 | 96.0           |      |      |                |     |
|       | 57                    | PI, mo 6   | 100.0                | 100.0|      | 98.3           | 98.3 |      |                |     |

\( a \) If the number between the two groups was different, the lowest number was taken.  
\( b \) Pre, sample taken prior to vaccination; PI to PIV, postdose months 1 to 4, respectively; mo 1, mo 2, etc., study month 1, study month 2, etc.
of anti-HBs antibody as the sample and standard diluent without affecting sample concentration determination.

Accuracy of recovery. The spiking experiments were performed on two different days. Recovery was calculated by expressing the measured concentrations in percentage of the theoretical concentration. Recovery ranged from 79.3% to 101.2%. The geometric mean recovery was 94.89% (95% CI, 92.24% to 97.62%) (Table 3). Accordingly, the anti-HBs in-house assay is considered to be accurate vis-à-vis the 1st IRP for anti-HBV immunoglobulin (1977-W1042).

Precision. A random three-way ANOVA with day, operator, and sample as random factor was carried out (using proc mixed of SAS) on log10-transformed concentrations. Computations were done on transformed values, but CVs were expressed from nontransformed concentrations. The CV for repeatability of the assay was 4.72%. The global CV reproducibility and repeatability under routine conditions were 11.86%. Precision is in agreement with what is currently displayed by the ELISA (6).

Linearity and parallelism. A mixed model was used with the factors log dilution (fixed and continuous), group (fixed, four groups), and samples (random, nested into the groups, 10 samples). The test for curvature of the log dilution effect was not statistically significant (P value of 0.5940). Consequently a linear model was fit to the data (Fig. 2). The test of the interaction of the log dilution and the group factors gave a nonsignificant P value of 0.8903, meaning that the log dilution effect (slope) can be considered equal from one group to another. The P value of the interaction between the log dilution and the sample factors was nonsignificant (0.24526), meaning that the slope of one sample is equal to the slope of another within each group. Finally, the estimated slope with its 95% CI was calculated for each group (Table 4). None of the slopes was significantly different from −1, supporting the proportionality between dilutions. Consequently linearity and parallelism are demonstrated over the analytical range.

Specificity. As shown in Table 5, the specificity of the anti-HBs in-house assay is around 100%, similar to the specificity displayed by the AUSAB EIA.

Hook effect. The three undiluted samples gave a higher response than that displayed by the upper standard point, for which the response was an OD of 3.0 in this experiment (upper standard specifications, ODs of 2.5 to 3.3) (Fig. 3). In addition, the CV calculated at dilutions of 10,000 and 100,000 was as good as 2% (Table 6). Concentrations as high as 823,976 mIU/ml can be reliably measured with the new assay without displaying any hook effect.

Clinical cutoff and correlation with the AUSAB RIA. Table 7 displays the overall agreement, specificity, and sensitivity for the comparison of the anti-HBs in-house assay and AUSAB RIA during the technical validation of the assay. The cutoff of the anti-HBs in-house assay was fixed at a value above the LOQ, which gave the best balance with respect to overall agreement, sensitivity, and specificity vis-à-vis the reference assay while keeping a nonsignificant P value for the McNemar test of dissymmetry in concordance. Accordingly, the cutoff was fixed at 3.3 mIU/ml. At this level, the overall agreement was 97.61% (CI, 96.40 to 98.49%), with a sensitivity and a specificity calculated at 98.04% (CI, 96.84 to 98.88%) and 94.06% (CI, 87.52 to 97.79%), which were considered as good. Deming’s regression was performed on the double-positive samples (n = 802) considering a CV at 11.86% as determined during the repeatability and reproducibility experiment (Fig. 4).
Finally, regression was considered as good between the anti-HBs in-house assay and the AUSAB RIA. Fuller’s coefficient of correlation (simple correction on the AUSAB RIA) was calculated to be 0.9815, which can be considered as high. The estimation of the slope and its 95% CI limit were established at 0.9187 (CI, 0.9060 to 0.9315). However in Table 8, the test of the bioequivalence of the slope was demonstrated because the 95% CI was within the 0.90 to 1.11 equivalence range (12, 14).

**Analytical range.** The lower limit of the analytical range usually corresponds to the LOQ of the assay. However we elected to use the cutoff for positivity in order to increase confidence in the assay. Thus, the lower limit of the analytical range was set at 3.3 mIU/ml. The upper analytical range was fixed at 187.0 mIU/ml, the level at which the accuracy is still effective (see “The calibration curve and its fitting algorithm”).

**Clinical validation of the assay.** Seroprotection rates observed with the anti-HBs in-house and reference assays in seven clinical trials are summarized in Table 9. Figure 5 shows anti-HBs GMCs using the in-house and reference assays in three studies representative of different age groups.

Study B investigated immune responses to HBV vaccination in nonresponder subjects who had received at least four doses of the Engerix HBV vaccine and was included in order to verify that those nonresponders would not have been considered as protected by the anti-HBs in-house assay, which would be an expression of a lack of specificity of the new assay. Out of 96 subjects assessed as seronegative at the study start with the AUSAB RIA, 9 were assessed as seropositive with the anti-HBs in-house assay. Accordingly, the specificity was calculated at 90.6% at the study start (data not shown). However, out of these nine samples, seven were confirmed as seropositive with the AUSAB EIA. At this stage, this apparent suboptimal specificity could be linked to a better sensitivity of the anti-HBs in-house assay and AUSAB EIA than that of the AUSAB RIA. These nonresponders then participated in a new trial (mentioned as study B in Table 9). The final analysis performed on study B after the complete vaccine course showed similar seroprotection rates and similar geometric mean antibody titers (GMTs) determined with either the anti-HBs in-house assay or the AUSAB RIA. Overall, the specificity of the anti-HBs in-house assay compared to the AUSAB RIA determined on a normal population was found to be 94.06% (see “Clinical cutoff and correlation with AUSAB RIA”), which was considered good.

In the reanalysis of seven studies in which different recombinant HBsAg-containing vaccines were used, a very good agreement in terms of seroprotection rate was observed after a full schedule and also 1 month postvaccination. Antibody GMCs were similar across the in-house and reference assays, with a trend toward overestimation using the in-house assay in the lower concentration range. Importantly, there was no evidence that the use of the anti-HBs in-house assay would lead to different clinical conclusions compared to the reference assays.

**DISCUSSION**

The new anti-HBs in-house assay has been developed to replace use of a commercial assay soon to be removed from the market. The performance characteristics of the new in-house assay have been thoroughly tested and are acceptable. Clinical application of the in-house assay has been documented by reanalysis of 4,180 samples from individuals of all ages participating in clinical trials of recombinant HBsAg-containing vaccines. In these studies, seroprotection rates and anti-HBs GMCs for individual studies were similar using either the in-house assay or the reference assays. In all studies, the immunogenicity conclusions determined by the reference assay were confirmed using the in-house assay.

The specificity of the anti-HBs in-house assay determined in study B was 90.6%, but this figure was calculated at the study start and in nonresponder subjects having received at least four doses of hepatitis B vaccine. After the full schedule, seroprotection rates and GMTs were similar for the anti-HBs in-house assay and the reference assay.

In conclusion, the new in-house anti-HBs antibody assay has been technically and clinically validated and displays adequate performance characteristics. There is no indication that use of the new assay would lead to different clinical conclusions from the currently used reference methods.

**ACKNOWLEDGMENTS**

The assay was developed and supported by GlaxoSmithKline Biologicals. On behalf of GlaxoSmithKline Biologicals, we thank Joanne Wolter, Veronique Delpire, Vidiya Virajith, and Manjula K for assistance with manuscript preparation, as well as ensuring manuscript coordination.

All authors of this article are employed by the commercial entity which has developed the in-house assay. J. Jacquet is also a shareholder of GlaxoSmithKline Biologicals.

**REFERENCES**

1. Barker, L. F., D. Lorenz, S. C. Rastogi, J. S. Finlayson, and E. B. Seligmann. 1977. Study of a proposed international reference preparation for anti-hepatitis B immunoglobulin. Expert Committee on Biological Standardization technical report series. World Health Organization, Geneva Switzerland.

2. Braggio, S., R. J. Barnaby, P. Grossi, and M. Cugola. 1996. A strategy for validation of bioanalytical methods. J. Pharm. Biomed. Anal. 14:375–388.

3. Findlay, J. W. A., W. C. Smith, J. W. Lee, G. D. Nordblom, I. Das, B. S. DeSilva, M. N. Khan, and R. R. Bowsher. 2000. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 24:1259–1273.

4. Hauser, P., P. Voet, E. Simoen, H. C. Thomas, J. Pétre, M. De Wilde, and J. Stephene. 1987. Immunological properties of recombinant HBsAg produced in yeast. Postgrad. Med. J. 63:85–91.

5. Keating, G. M., and S. Noble. 2003. Recombinant hepatitis B vaccine (Engerix®-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 63:1021–1051.

6. Miller, K. J., R. R. Bowsher, A. Cehniker, J. Gibbons, S. Gupta, J. W. Lee, S. J. Swanson, W. C. Smith, and R. S. Weiner. 2001. Workshop on bioanalytical methods validation for macromolecules: summary report. Pharmacol. Res. 41:1373–1383.

7. Nakane, P. K., and A. Kawaoi. 1974. Peroxidase-labeled antibody. A new method of conjugation. J. Histochem. Cytochem. 22:1084–1091.

8. Pétre, J., F. Van Wijnendaele, B. De Neys, K. Konrath, O. Van Opstal, P. Hauser, T. Rutgers, T. Cabezón, C. Capiau, N. Harford, et al. 1987. Development of a hepatitis B vaccine from transformed yeast cells. Postgrad. Med. J. 63(Suppl. 2):73–81.

9. Plikatitis, B. D., S. H. Turner, L. L. Gheesling, and C. M. Carbone. 1991. Comparison of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody level by enzyme-linked-imunosorbent assay. J. Clin. Microbiol. 29:1439–1446.

10. Rodbard, D., and G. R. Frazier. 1975. Statistical analysis of radioligand assay data. Methods Enzymol. 37:3–22.

11. Soulier, J. P., and A. M. Couroucé-Pauty. 1973. New determinants of hepatitis B antigen (Au or HB antigen). Vox Sang. 25:212–234.

12. Tan, C. Y., and B. Iglewicz. 1999. Measurement-methods comparisons and linear statistical relationship. Technometrics 41:192–201.

13. U.S. Department of Health and Human Services, Food and Drug Admin-

Vol. 16, 2009

QUANTITATIVE ELISA FOR DETECTION OF ANTI-HBsAg
istration Center for Drug Evaluation, and Research Center for Veterinary Medicine. 2001. Guidance for industry. Bioanalytical method validation. U.S. Department of Health and Human Services, Washington, D.C.

14. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. 2001. Guidance for industry. Statistical approaches to establish bioequivalence. U.S. Department of Health and Human Services, Washington, D.C.

15. Vnek, J., and A. M. Prince. 1976. Large-scale purification of hepatitis B surface antigen. J. Clin. Microbiol. 36:626–631.

16. World Health Organization. 2004. Hepatitis B vaccines W.H.O. position paper. Wkly. Epidemiol. Rep. 79:255–263.